



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Oxaliplatin (Eloxatin®) as Adjuvant (Combination)
Chemotherapy for Completely Resected Stage III Rectal Cancer
Capital District Health Authority / Cancer Care Nova Scotia**

Approved Use:

Oxaliplatin: In combination with 5-FU/LV infusional based chemotherapy (FOLFOX) as adjuvant therapy in patients who have documented evidence of **completely resected stage III rectal cancer**, with an ECOG performance status of 0-2, for whom adjuvant chemotherapy would be recommended.

- This policy recommendation represents an **expansion** of existing criteria and a restriction of oxaliplatin to include completely resected stage III rectal cancer patients.

Approved by: _____

Chair, CSTPC

Date: _____